MAP2K7 and cancer: Aberrant activation of the EGFR signaling pathway is critical for cancer cell apoptosis, proliferation, differentiation, and motility via the downstream RAS/RAF/MEK/ERK and AKT/PI3K/mTOR pathways (57, 58), and tremendous amounts of research have implicated EGFR as a potential target for cancer therapy (59).